An Analysis of Efficacy of Maintenance Dasatinib for Ph+ALL Patients after Allogeneic Hematopoietic Stem Cell Transplantation: Prospective Phase II trial

Trial Profile

An Analysis of Efficacy of Maintenance Dasatinib for Ph+ALL Patients after Allogeneic Hematopoietic Stem Cell Transplantation: Prospective Phase II trial

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms DASALL II
  • Most Recent Events

    • 19 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top